Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Guerci

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Blood|November 1, 1992
All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 casesP Fenaux, S Castaigne, H Dombret, et al.
Blood|July 15, 1994
Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL GroupP Fenaux, E Wattel, E Archimbaud, et al.
Journal of Neurochemistry|February 1, 1986
Schwann cell marker defined by a monoclonal antibody (224-58) with species cross-reactivity. I. Cellular localizationA Guerci, M Monge, A Baron-Van Evercooren, et al.
Leukemia|February 20, 2003
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blastsV Ribrag, F Suzan, C Ravoet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'AdulteA Guerci, P Lederlin, F Reyes, et al.
Blood|December 1, 1993
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 GroupP Fenaux, M C Le Deley, S Castaigne, et al.
The New England Journal of Medicine|July 24, 1997
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupF Guilhot, C Chastang, M Michallet, et al.
Journal of the American College of Cardiology|December 19, 1998
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trialK P Alexander, E D Peterson, C B Granger, et al.
Journal of the American College of Cardiology|January 13, 1998
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary ArteriesA Betriu, R M Califf, X Bosch, et al.
JAMA|May 24, 1995
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesF Van de Werf, E J Topol, K L Lee, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Blood|November 1, 1992
All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 casesP Fenaux, S Castaigne, H Dombret, et al.
Blood|July 15, 1994
Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL GroupP Fenaux, E Wattel, E Archimbaud, et al.
Journal of Neurochemistry|February 1, 1986
Schwann cell marker defined by a monoclonal antibody (224-58) with species cross-reactivity. I. Cellular localizationA Guerci, M Monge, A Baron-Van Evercooren, et al.
Leukemia|February 20, 2003
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blastsV Ribrag, F Suzan, C Ravoet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'AdulteA Guerci, P Lederlin, F Reyes, et al.
Blood|December 1, 1993
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 GroupP Fenaux, M C Le Deley, S Castaigne, et al.
The New England Journal of Medicine|July 24, 1997
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupF Guilhot, C Chastang, M Michallet, et al.
Journal of the American College of Cardiology|December 19, 1998
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trialK P Alexander, E D Peterson, C B Granger, et al.
Journal of the American College of Cardiology|January 13, 1998
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary ArteriesA Betriu, R M Califf, X Bosch, et al.
JAMA|May 24, 1995
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesF Van de Werf, E J Topol, K L Lee, et al.
Pageof 8